UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-04, Vol.29 (12), p.1556-1563

2011

Volltextzugriff (PDF)

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

The American journal of pathology, 2011-03, Vol.178 (3), p.989-996

2011

Volltextzugriff (PDF)

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

Journal of investigative dermatology, 2013-06, Vol.133 (6), p.1582-1590

2013

Volltextzugriff (PDF)

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1051-1058

2008

Volltextzugriff (PDF)

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-07, Vol.14 (1), p.4444-4444, Article 4444

2023

Volltextzugriff (PDF)

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

Journal of clinical oncology, 2010-02, Vol.28 (6), p.967-975

2010

Volltextzugriff (PDF)

Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)

Journal of bone and mineral research, 2006-08, Vol.21 (8), p.1215-1223

2006

Volltextzugriff (PDF)

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-08, Vol.14 (1), p.4741-4741, Article 4741

2023

Volltextzugriff (PDF)

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Journal of bone and mineral research, 2010-03, Vol.25 (3), p.463-471

2010

Volltextzugriff (PDF)

Biomarkers in oncology drug development

Molecular oncology, 2009-02, Vol.3 (1), p.24-32

2009

Volltextzugriff (PDF)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5213-5224

2021

Volltextzugriff (PDF)

Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

Journal of thoracic oncology, 2012-02, Vol.7 (2), p.306-315

2012

Volltextzugriff (PDF)

A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS3170-TPS3170

2024

Volltextzugriff (PDF)

Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma

Melanoma research, 2014-02, Vol.24 (1), p.40-46

2014

Volltextzugriff (PDF)

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement

British journal of cancer, 2020-02, Vol.122 (4), p.473-482

2020

Volltextzugriff (PDF)

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

Cancer chemotherapy and pharmacology, 2008-01, Vol.61 (1), p.23-32

2008

Volltextzugriff (PDF)

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS13-05-PS13-05

2021

Volltextzugriff (PDF)

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

The oncologist (Dayton, Ohio), 2023-12, Vol.28 (12), p.e1248-e1258

2023

Volltextzugriff (PDF)

Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14674-e14674

2019

Volltextzugriff (PDF)

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-10

2022

Volltextzugriff (PDF)

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS3-10-GS3-10

2022

Volltextzugriff (PDF)

A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11517-11517

2020

Volltextzugriff (PDF)

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4791-4791

2018

Volltextzugriff (PDF)

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

The Journal of molecular diagnostics : JMD, 2014-05, Vol.16 (3), p.343-349

2014

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBreast Cancer Research And Treatment

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(20)
Oncology
(14)
Female
(12)
Male
(10)
Middle Aged
(10)
Aged
(9)
Biological And Medical Sciences
(8)
Medical Sciences
(7)
Tumors
(7)
Adult
(5)
Neoplastic Cells, Circulating - Pathology
(5)
Aged, 80 And Over
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Biomarkers, Tumor - Metabolism
(4)
Bone Remodeling - Drug Effects
(4)
Treatment Outcome
(4)
Aromatase Inhibitors - Adverse Effects
(3)
Bone Density - Drug Effects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Biomarkers in oncology drug development

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies

Clinical development of new drug–radiotherapy combinations

Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Aktive Filter

Suchergebnisse filtern